What is Leerink Partnrs’ Estimate for Quanterix Q1 Earnings?

Quanterix Co. (NASDAQ:QTRX) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Quanterix in a research note issued to investors on Monday, March 17th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.69) per share for the quarter, down from their prior forecast of ($0.58). The consensus estimate for Quanterix’s current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($1.05) EPS.

Quanterix (NASDAQ:QTRX) last released its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The company had revenue of $35.16 million during the quarter, compared to analysts’ expectations of $34.93 million.

Separately, Canaccord Genuity Group decreased their target price on Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday.

Quanterix Stock Performance

Quanterix stock opened at $7.24 on Thursday. Quanterix has a 52 week low of $6.30 and a 52 week high of $26.18. The firm has a market capitalization of $278.91 million, a PE ratio of -6.83 and a beta of 1.34. The business’s 50-day simple moving average is $8.23 and its 200-day simple moving average is $10.88.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in QTRX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Quanterix by 2.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 520,869 shares of the company’s stock worth $5,537,000 after purchasing an additional 10,111 shares during the period. Williams Jones Wealth Management LLC. increased its position in shares of Quanterix by 39.9% in the fourth quarter. Williams Jones Wealth Management LLC. now owns 471,514 shares of the company’s stock valued at $5,012,000 after acquiring an additional 134,470 shares during the last quarter. Two Sigma Advisers LP increased its holdings in Quanterix by 35.9% during the fourth quarter. Two Sigma Advisers LP now owns 36,748 shares of the company’s stock worth $391,000 after buying an additional 9,700 shares during the last quarter. Two Sigma Investments LP bought a new position in Quanterix during the fourth quarter worth about $606,000. Finally, ProShare Advisors LLC acquired a new position in shares of Quanterix during the 4th quarter worth approximately $108,000. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.